Mosis G, Gutierrez LP, Dieleman J, Castellsague J, Sturkenboom M. No changes in channeling of COX-2 Specific inhibitors in the first three years after marketing. Poster presented at the ISoP Annual Conference ‘Pharmacovigilance in Clinical Practice’; October 2003. Marrakech, Morocco. [abstract] Pharmacoepidemiol Drug Saf. 2003 Oct; 12(S2):S243.
Mines DI, Wang L, Guo D, Xue S. The incidence of Myasthenia Gravis (MG) in the General Practice Research Database (GPRD): a validation study. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th International Conference on Pharmacoepidemiology; August 22, 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1).
Gimeno V, Castellsague J, Varas-Lorenzo C, Hopkins JS, Eaton SC, Perez-Gutthann S. Gastrointestinal and cardiovascular characterization of users of COX-2 specific inhibitors. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):43.
Garcia-Rodriguez LA, Varas-Lorenzo C, Maguire A, Castellsague J, Gonzalez-Perez A, Perez-Gutthann S, Arellano A. Non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and the risk of acute myocardial infarction in the UK. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):117.
Arana A, Castellsague J, Trave F, Perez-Gutthann S, Rothman KJ, Arellano FM. Early estimation of excess risk of serious cutaneous reactions for newly marketed drugs. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):165.
Varas-Lorenzo C, Maguire A, Perez-Gutthann S. Serum potassium levels, hypertension and antihypertensive treatment in the US adult population: NHANES III (1988-1994). Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):54.
Rivero E, Huerta C, Garcia-Rodriguez LA, Fernandez-Vidaurre C, Abrams BB. The risk of lymphoid neoplasms and other hematological malignancies in patients with atopic dermatitis. Poster presented at the 19th International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(Suppl 1):S110-1.
Arana A, Broeckmans AW. Validity of epidemiological research conducted following Good Clinical Practice Guidelines. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.
Sánchez Matienzo D, Gimeno V, Castellsague J, Arana A. A comparative safety profile of serious skin and hypersensitivity reactions: cOX-s specific inhibitors vs. non-selective NSAIDs and other selected drugs. Presented at the 19th International Conference on Pharmacoepidemiology; 2003. [abstract] Pharmacoepidemiol Drug Saf. 2003; 12(S1):S185.
Sánchez Matienzo D, Gemino V, Castellsague J, Arana A. Safety profile analysis of liver disorders in patients treated with celecoxib and rofecoxib. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.